RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
872. Drueke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A,
Kreis H. Atherosclerosis and lipiddisorders after renal transplantation.
Kidney Int 39 (suppl 31): S24-S28, 1991.
873. Abdulmassih Z, Chevalier A, Bader C, y cols. Role of lipid
disturbances in the atherosclerosis of renal transplant
patients. Clin Transplant 6: 106-113, 1992
874. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk
factor and diseases after renal transplantation. In Urol
Nephrol 30: 777-788, 1998
875. Aakhus S, Dahl K, Winderoe TE. Cardiovascular morbidity
and risk factors in renal transplant patients. Nephrol Dial
Transplant 14: 648-654, 1999
876. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA,
Ibels LS. hyperlipidemia in renal transplant recipients:
Natural history and response to treatment. Medicine 1994;
73: 215-223, 1994
877. Barbagallo CM, Pinto A, Gallo S, Parrinello G, Caputo F,
Sparacino V y cols. Carotid atherosclerosis in renal transplant
recipients: relationships with cardiovascular risk factors
and plasma lipoproteins. Transplantation 67: 366-371,
1999
878. Massy ZA, Mamzer-Bruneel MF, Chevalier A, Millet P,
Helenon O, Chadefaux-Vekemans B, y cols. Carotid atherosclerosis
in renal transplant recipients. Nephrol Dial
Transplant 13: 1792-1798, 1998
879. Dimeny E, Fellström B, Larsson E, Tufveson G, Lithell H.
Hyperlipoproteinemia in renal transplant recipients: is there
a linkage with chronic vascular rejection? Transplant Proc
25: 2065-2066, 1993
880. Dimeny E, Fellström B, Larsson E, y cols. Chronic vascular
rejection and hyperlipoproteinemia in renal transplant
patients. Clin Transplant 7:482-490, 1993
881. Isoniemi H, Nurminen M, Tikkanen MJ, von Willebrand E,
Krogerus L, Ahonen J y cols. Risk factors predicting chronic
rejection of renal allografts. Transplantation 57: 68-72, 1994
882. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL.
Chronic allograft rejection: immunologic and non immunologic
risk factors. Kidney Int 49. 518-524, 1996
883. Roodnat JL, Mulder PG, Zietse R, Rischen-Vos J, van
Riemsdijk IC, Ijzermans JN y cols. Cholesterol as an independent
predictor of outcome after renal transplantation.
Transplantation 69: 1704-1710, 2000
884. Kronenberg F, Konig P, Lhotta K, Ofner D, Sandholzer C,
Margreiter R y cols. Apolipoprotein(a) phenotype associated
decrease in lipoprotein(a) plasma concentrations after renal
transplantation. Arterioscler Thromb 14: 1399-1404, 1994
885. Black JW, Wilcken DE. Decreases in apolipoprotein(a) after
renal transplantation: implications for lipoprotein(a) metabolism.
Clin Chem 38: 353-357, 1992
886. Webb AT, Plant M, Reaveley DA, O'Donnell M, Luck VA,
O'Connor B, y cols. Lipid and lipoprotein(a) concentrations
in renal transplant patients. Nephrol Dial Transplant 7: 636-
641, 1992
887. Holdaas H, Fellström B, Jardine A, Holme I, Nyberg G,
Fauchald P, y cols. Effect of fluvastatin on cardiac outcomes
in renal transplant recipients: a multicentre, randomised,
placebo-controlled trial. Lancet 361: 2024-2031, 2003
888. Clinical practice guidelines for managing dyslipidemias in
kidney transplant patients. A report from the Managing
Dyslipidemias in Chronic Kidney Disease Work Group of
the National Kidney Foundation Kidney disease Outcomes
Quality Initiative. National Kidney Foundation Work Group
Members: B. Kasiske, F.G. Cosio, J. Beto, K. Bolton, B.M.
Chavers, R. Grimm Jr. A. Levin, B. Masri, R. Parekh, C.
Wanner, D.C. Wheeler and P.W.F. Wilson. Am J Transplant
4(suppl 7): 13-53, 2004
889. Kasiske BL, O`Donnell MP, Cleary MP, Keane WF. Treatment
of hyperlipidemia reduces glomerular injuries in obese
Zucker rats. Kidney Int 33: 667-672, 1988
890. Kasiske BL, O`Donnell MP, Garvis WJ, Keane WF.
Pharmacological treatment of hyperlipidemia reduces glomerular
injury in 5/6 nephrectomy rat model of CRF. Circ
Res 62: 367-374, 1988
891. Harris KPG, Pukerson ML, Yates J, Klahr S. Lovastatin ameliorates
the development of glomerulosclerosis and uremia
in experimental nephritic syndrome. Am J Kidney Dis 50:
16-23, 1990
892. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni
S, y cols. Effect of combining ACE inhibitor and statin in
severe experimental nephropathy. Kidney Int 61: 1635-
1645, 2002
893. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani
C, y cols. How to fully protect the kidney in a severe model
of progressive nephropathy: a multidrug approach. J Am Soc
Nephrol 13: 2898-2908, 2002
894. Fried L, Orchard T, Kasiske B. Effect of lipid reduction on the
progression of renal disease; a metaanalysis. Kidney Int 59:
260- 269, 2001
895. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol,
a nicotinic acid derivate, in chronic renal disease with
hyperlipidemia: a randomized trial. Am J Med 114: 347-353,
2003
896. MRC/BHF Heart Protection Study of cholesterol lowering
with simvastatin in 20536 high risk individuals: a randomised
placebo controlled trial. Lancet 360: 7-22, 2002
897. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD,
Cole TG y cols. The effect of pravastatin on coronary events
after myocardial infarction in patients with average cholesterol
levels. N Engl J Med 335: 1001-1009, 1996
898. Scandinavian Simvastatin Survival study Group: Randomised
trial of cholesterol lowering in 4444 patients with coronary
heart disease: the Scandinavian Simvastatin Survival Study
(4S). Lancet 344: 1383-1389, 1994
899. Long Term Intervention with Pravastatin in Ischaemic
Disease (LIPID) Study Group: Prevention of cardiovascular
events and death with pravastatin in patients with coronary
heart disease and a broad range of initial cholesterol levels.
N Engl J Med 339: 1349-1357, 1998
900. Shepherd J, Cobbe S, Ford I, Isles CG, Lorimer AR,
MacFarlane PW y cols. Prevention of coronary heart disease
with pravastatin in men with hypercholesterolemia. N Engl J
Med 333:1301-1307, 1995
901. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR,
Beere PA y cols. Primary prevention of acute coronary
events with lovastatin in men and women with average cholesterol
levels: results of AFCAPS/TexCAPS Air Force/Texas
Coronary Atherosclerosis prevention Study. JAMA 279:
1615-1622, 1998
902. Waters D, Schwartz G, Olsson A. The Myocardial Ischemia
Reduction with Acute Cholesterol Lowering (MIRACL) trial:
a new frontiers for statins? Curr Control Trials Cardiovascular
Med 2: 111-114, 2001
214